Substituted dihydrophenanthridinesulfonamides

A pharmaceutical composition, which comprises a compound of formulae (I) or (II) having the structure

• 19
• wherein
• R1, R2, R3, R4, R7, R8, R9, R10, R11, R12, R14, and R15 are each, independently, hydrogen, R17, monofluoroalkyl, monofluoroalkenyl, aryl-R16—, heteroaryl-R16—, hydroxyalkyl, HO—R16—, R17—X—R16—, HS—R16—, R17—S(O)—, R17—S(O)2—, R17—SO3—, R17—S(O)2NR—, —N(R)2, —NR—C(NH2)═NR, cyano, nitro, halogen, —OR, —SR, —SO3R, —S(O)2N(R)2, —C(O)R, —C(R)═N—OR, —C(NH2)═NR, —CO2R, —OC(O)R, or —C(O)N(R)2;
• or are taken together with either Rp+1 or Rp−1 linked with an -alkylene-, or —X-alkylene-group;
• R5 is hydrogen, R17, monofluoroalkyl, monofluoroalkenyl, aryl-R16—, heteroaryl-R16—, hydroxyalkyl, HO—R16—, R17—X—R16—, HS—R16—, —CR(O), —CO2R, or —C(O)N(R)2;
• or R5 may be taken together with either R6 or R7 and linked with an -alkylene- or —X-alkylene-group;
• R6 is hydrogen, R17, monofluoroalkyl, monofluoroalkenyl, aryl-R16—, heteroaryl-R16—, hydroxyalkyl, HO—R16—, R17—X—R16—, HS—R16—, —CR(O), —CO2R, or —C(O)N(R)2;
• or R6 may be taken together with either R5 or R7 and linked with an -alkylene- or —X-alkylene-group;
• R13 is R, R17—X—R16—, R17—S(O)—, R17—S(O)2—, —SO3R, —S(O)2N(R)2, or D-glucuronidate;
• R16 is -alkylene-, -cycloalkylene-, -alkylene-X-alkylene-, -alkylene-X-cycloalkylene-, -cycloalkylene-X-alkylene-, or -cycloalkylene-X-cycloalkylene-;
• R17 is alkyl, aryl, heteroaryl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, alkenyl-X-alkylene-, cycloalkenyl-X-alkylene-, or perfluoroalkyl;
• R is, independently, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, monofluoroalkyl, perfluoroalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy-(C2-C6)alkyl, alkoxyalkyl, alkylthioalkyl, formyl, acyl, alkoxycarbonyl, —C(O)NH2, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminoalkyl, or dialkylaminoalkyl;
• or when an atom contains two R groups, the R groups may be taken together linked with an -alkylene-group;
• X is O, —NR—, —S(O)m—, —C(O)—, —OC(O)—, —C(O)O—, —NRC(O)—, or —C(O)NR—;
• m is 0, 1, or 2;
• p is 2, 3, 6, 7, 8, 9, 12, 13, or 14;
• R21, R22, R23, R24, R27, R28, R29, R30, R31, R33, R34, and R35 are, independently, hydrogen, R17;
• monofluoroalkyl, monofluoroalkenyl, aryl-R16—, heteroaryl-R16—, hydroxyalkyl, HO—R16—, R17—Y—R16—, HS—R16—, R17—S(O)—, R17—S(O)2—, R17—SO3—, R17—S(O)2NR—, —N(R)2, —NR—C(NH2)═NR, cyano, nitro, halogen, —OR, —SR, —SO3R, —S(O)2N(R)2, —C(O)R, —C(R)═N—OR, —C(NH2)═NR, —CO2R, —OC(O)R, or —C(O)N(R)2;
• or are taken together with either Rq+1 or Rq−1 linked with an -alkylene-, or —Y-alkylene-group;
• R25 is hydrogen, R17, monofluoroalkyl, monofluoroalkenyl, aryl-R16—, heteroaryl-R16—, hydroxyalkyl, HO—R16—, R17—Y—R16—, HS—R16—, —CR(O), —CO2R, or —C(O)N(R)2;
• or R25 may be taken together with either R26 or R27 and linked with an -alkylene- or —Y-alkylene-group;
• R26 is hydrogen, R17, monofluoroalkyl, monofluoroalkenyl, aryl-R16—, heteroaryl-R16—, hydroxyalkyl, HO—R16—, R17—Y—R16—, HS—R1 6—, —CR(O), —CO2R, or —C(O)N(R)2;
• or R26 may be taken together with either R25 or R27 and linked with an -alkylene- or —Y-alkylene-group;
• R32 is R, R17—Y—R16—, R17—S(O)—, R17—S(O)2—, —SO3R, —S(O)2N(R)2, or D-glucuronidate;
• Y is O, —NR—, —S(O)n—, —C(O)—, —OC(O)—, —C(O)O—, —NRC(O)—, or —C(O)NR—;
• n is 0, 1, or 2;
• q is 22, 23, 26, 27, 28, 29, 32, 33, or 34;
• or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.